Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top Medicine for Osteoarthritis Pain Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Medicine for Osteoarthritis Pain Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Oral
1.3.3 Injection
1.3.4 External
1.4 Market Segment by Application
1.4.1 Global Medicine for Osteoarthritis Pain Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Medical Care
1.4.3 Personal Care
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Medicine for Osteoarthritis Pain Revenue (2015-2026)
2.1.1 Global Medicine for Osteoarthritis Pain Revenue (2015-2026)
2.1.2 Global Medicine for Osteoarthritis Pain Sales (2015-2026)
2.2 Medicine for Osteoarthritis Pain Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Medicine for Osteoarthritis Pain Sales by Regions (2015-2020)
2.2.2 Global Medicine for Osteoarthritis Pain Revenue by Regions (2015-2020)
2.3 Global Top Medicine for Osteoarthritis Pain Regions (Countries) Ranking by Market Size
2.4 Medicine for Osteoarthritis Pain Industry Trends
2.4.1 Medicine for Osteoarthritis Pain Market Top Trends
2.4.2 Market Drivers
2.4.3 Medicine for Osteoarthritis Pain Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Medicine for Osteoarthritis Pain Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top Medicine for Osteoarthritis Pain Manufacturers by Sales (2015-2020)
3.1.1 Global Medicine for Osteoarthritis Pain Sales by Manufacturers (2015-2020)
3.1.2 Global Medicine for Osteoarthritis Pain Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Medicine for Osteoarthritis Pain Sales in 2019
3.2 Global Top Manufacturers Medicine for Osteoarthritis Pain by Revenue
3.2.1 Global Medicine for Osteoarthritis Pain Revenue by Manufacturers (2015-2020)
3.2.2 Global Medicine for Osteoarthritis Pain Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Medicine for Osteoarthritis Pain Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Medicine for Osteoarthritis Pain as of 2019)
3.4 Global Medicine for Osteoarthritis Pain Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Medicine for Osteoarthritis Pain Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Medicine for Osteoarthritis Pain Market
3.7 Key Manufacturers Medicine for Osteoarthritis Pain Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Medicine for Osteoarthritis Pain Historic Market Review by Type (2015-2020)
4.1.2 Global Medicine for Osteoarthritis Pain Sales Market Share by Type (2015-2020)
4.1.3 Global Medicine for Osteoarthritis Pain Revenue Market Share by Type (2015-2020)
4.1.4 Medicine for Osteoarthritis Pain Price by Type (2015-2020)
4.1 Global Medicine for Osteoarthritis Pain Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Medicine for Osteoarthritis Pain Sales Forecast by Type (2021-2026)
4.2.3 Global Medicine for Osteoarthritis Pain Revenue Forecast by Type (2021-2026)
4.2.4 Medicine for Osteoarthritis Pain Price Forecast by Type (2021-2026)
5 Global Medicine for Osteoarthritis Pain Market Size by Application
5.1 Global Medicine for Osteoarthritis Pain Historic Market Review by Application (2015-2020)
5.1.2 Global Medicine for Osteoarthritis Pain Sales Market Share by Application (2015-2020)
5.1.3 Global Medicine for Osteoarthritis Pain Revenue Market Share by Application (2015-2020)
5.1.4 Medicine for Osteoarthritis Pain Price by Application (2015-2020)
5.2 Global Medicine for Osteoarthritis Pain Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Medicine for Osteoarthritis Pain Sales Forecast by Application (2021-2026)
5.2.3 Global Medicine for Osteoarthritis Pain Revenue Forecast by Application (2021-2026)
5.2.4 Medicine for Osteoarthritis Pain Price Forecast by Application (2021-2026)
6 North America
6.1 North America Medicine for Osteoarthritis Pain Breakdown Data by Company
6.2 North America Medicine for Osteoarthritis Pain Breakdown Data by Type
6.3 North America Medicine for Osteoarthritis Pain Breakdown Data by Application
6.4 North America Medicine for Osteoarthritis Pain Breakdown Data by Countries
6.4.1 North America Medicine for Osteoarthritis Pain Sales by Countries
6.4.2 North America Medicine for Osteoarthritis Pain Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Medicine for Osteoarthritis Pain Breakdown Data by Company
7.2 Europe Medicine for Osteoarthritis Pain Breakdown Data by Type
7.3 Europe Medicine for Osteoarthritis Pain Breakdown Data by Application
7.4 Europe Medicine for Osteoarthritis Pain Breakdown Data by Countries
7.4.1 Europe Medicine for Osteoarthritis Pain Sales by Countries
7.4.2 Europe Medicine for Osteoarthritis Pain Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Medicine for Osteoarthritis Pain Breakdown Data by Company
8.2 Asia Pacific Medicine for Osteoarthritis Pain Breakdown Data by Type
8.3 Asia Pacific Medicine for Osteoarthritis Pain Breakdown Data by Application
8.4 Asia Pacific Medicine for Osteoarthritis Pain Breakdown Data by Regions
8.4.1 Asia Pacific Medicine for Osteoarthritis Pain Sales by Regions
8.4.2 Asia Pacific Medicine for Osteoarthritis Pain Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Medicine for Osteoarthritis Pain Breakdown Data by Company
9.2 Latin America Medicine for Osteoarthritis Pain Breakdown Data by Type
9.3 Latin America Medicine for Osteoarthritis Pain Breakdown Data by Application
9.4 Latin America Medicine for Osteoarthritis Pain Breakdown Data by Countries
9.4.1 Latin America Medicine for Osteoarthritis Pain Sales by Countries
9.4.2 Latin America Medicine for Osteoarthritis Pain Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Medicine for Osteoarthritis Pain Breakdown Data by Type
10.2 Middle East and Africa Medicine for Osteoarthritis Pain Breakdown Data by Application
10.3 Middle East and Africa Medicine for Osteoarthritis Pain Breakdown Data by Countries
10.3.1 Middle East and Africa Medicine for Osteoarthritis Pain Sales by Countries
10.3.2 Middle East and Africa Medicine for Osteoarthritis Pain Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Pfizer Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Pfizer Medicine for Osteoarthritis Pain Products and Services
11.1.5 Pfizer SWOT Analysis
11.1.6 Pfizer Recent Developments
11.2 Johnson and Johnson
11.2.1 Johnson and Johnson Corporation Information
11.2.2 Johnson and Johnson Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Johnson and Johnson Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Johnson and Johnson Medicine for Osteoarthritis Pain Products and Services
11.2.5 Johnson and Johnson SWOT Analysis
11.2.6 Johnson and Johnson Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Business Overview and Total Revenue (2019 VS 2018)
11.3.3 GlaxoSmithKline Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline Medicine for Osteoarthritis Pain Products and Services
11.3.5 GlaxoSmithKline SWOT Analysis
11.3.6 GlaxoSmithKline Recent Developments
11.4 Bayer
11.4.1 Bayer Corporation Information
11.4.2 Bayer Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Bayer Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Bayer Medicine for Osteoarthritis Pain Products and Services
11.4.5 Bayer SWOT Analysis
11.4.6 Bayer Recent Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Corporation Information
11.5.2 Eli Lilly Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Eli Lilly Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Eli Lilly Medicine for Osteoarthritis Pain Products and Services
11.5.5 Eli Lilly SWOT Analysis
11.5.6 Eli Lilly Recent Developments
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Novartis Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Novartis Medicine for Osteoarthritis Pain Products and Services
11.6.5 Novartis SWOT Analysis
11.6.6 Novartis Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Sanofi Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Sanofi Medicine for Osteoarthritis Pain Products and Services
11.7.5 Sanofi SWOT Analysis
11.7.6 Sanofi Recent Developments
11.8 Horizon Pharma
11.8.1 Horizon Pharma Corporation Information
11.8.2 Horizon Pharma Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Horizon Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Horizon Pharma Medicine for Osteoarthritis Pain Products and Services
11.8.5 Horizon Pharma SWOT Analysis
11.8.6 Horizon Pharma Recent Developments
11.9 Abbott
11.9.1 Abbott Corporation Information
11.9.2 Abbott Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Abbott Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Abbott Medicine for Osteoarthritis Pain Products and Services
11.9.5 Abbott SWOT Analysis
11.9.6 Abbott Recent Developments
11.10 Mylan
11.10.1 Mylan Corporation Information
11.10.2 Mylan Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Mylan Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Mylan Medicine for Osteoarthritis Pain Products and Services
11.10.5 Mylan SWOT Analysis
11.10.6 Mylan Recent Developments
11.11 Daiichi Sankyo
11.11.1 Daiichi Sankyo Corporation Information
11.11.2 Daiichi Sankyo Business Overview and Total Revenue (2019 VS 2018)
11.11.3 Daiichi Sankyo Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 Daiichi Sankyo Medicine for Osteoarthritis Pain Products and Services
11.11.5 Daiichi Sankyo SWOT Analysis
11.11.6 Daiichi Sankyo Recent Developments
11.12 TEVA
11.12.1 TEVA Corporation Information
11.12.2 TEVA Business Overview and Total Revenue (2019 VS 2018)
11.12.3 TEVA Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 TEVA Medicine for Osteoarthritis Pain Products and Services
11.12.5 TEVA SWOT Analysis
11.12.6 TEVA Recent Developments
11.13 Almatica Pharma
11.13.1 Almatica Pharma Corporation Information
11.13.2 Almatica Pharma Business Overview and Total Revenue (2019 VS 2018)
11.13.3 Almatica Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 Almatica Pharma Medicine for Osteoarthritis Pain Products and Services
11.13.5 Almatica Pharma SWOT Analysis
11.13.6 Almatica Pharma Recent Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Corporation Information
11.14.2 Astellas Pharma Business Overview and Total Revenue (2019 VS 2018)
11.14.3 Astellas Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.14.4 Astellas Pharma Medicine for Osteoarthritis Pain Products and Services
11.14.5 Astellas Pharma SWOT Analysis
11.14.6 Astellas Pharma Recent Developments
11.15 Tide Pharmaceutical
11.15.1 Tide Pharmaceutical Corporation Information
11.15.2 Tide Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.15.3 Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.15.4 Tide Pharmaceutical Medicine for Osteoarthritis Pain Products and Services
11.15.5 Tide Pharmaceutical SWOT Analysis
11.15.6 Tide Pharmaceutical Recent Developments
11.16 Iroko Pharmaceuticals
11.16.1 Iroko Pharmaceuticals Corporation Information
11.16.2 Iroko Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.16.3 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.16.4 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Products and Services
11.16.5 Iroko Pharmaceuticals SWOT Analysis
11.16.6 Iroko Pharmaceuticals Recent Developments
11.17 Hengrui Pharmaceutical
11.17.1 Hengrui Pharmaceutical Corporation Information
11.17.2 Hengrui Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.17.3 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.17.4 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Products and Services
11.17.5 Hengrui Pharmaceutical SWOT Analysis
11.17.6 Hengrui Pharmaceutical Recent Developments
11.18 Abiogen Pharma
11.18.1 Abiogen Pharma Corporation Information
11.18.2 Abiogen Pharma Business Overview and Total Revenue (2019 VS 2018)
11.18.3 Abiogen Pharma Medicine for Osteoarthritis Pain Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.18.4 Abiogen Pharma Medicine for Osteoarthritis Pain Products and Services
11.18.5 Abiogen Pharma SWOT Analysis
11.18.6 Abiogen Pharma Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Medicine for Osteoarthritis Pain Sales Channels
12.2.2 Medicine for Osteoarthritis Pain Distributors
12.3 Medicine for Osteoarthritis Pain Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.1.1 Global Medicine for Osteoarthritis Pain Sales Forecast by Regions (2021-2026)
13.1.2 Global Medicine for Osteoarthritis Pain Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.2.2 North America Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.2.3 North America Medicine for Osteoarthritis Pain Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.3.2 Europe Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.3.3 Europe Medicine for Osteoarthritis Pain Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.4.2 Asia Pacific Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Medicine for Osteoarthritis Pain Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.5.2 Latin America Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.5.3 Latin America Medicine for Osteoarthritis Pain Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Medicine for Osteoarthritis Pain Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Medicine for Osteoarthritis Pain Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Medicine for Osteoarthritis Pain Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Pfizer、Johnson and Johnson、GlaxoSmithKline、Bayer、Eli Lilly、Novartis、Sanofi、Horizon Pharma、Abbott、Mylan、Daiichi Sankyo、TEVA、Almatica Pharma、Astellas Pharma、Tide Pharmaceutical、Iroko Pharmaceuticals、Hengrui Pharmaceutical、Abiogen Pharma
【免責事項】
https://www.globalresearch.jp/disclaimer